Amgen to Acquire Otezla® from Celgene and BMS for $13.4 Billion
Amgen
Developer of Treatment Drugs for Serious Diseases
Celgene
Innovative Therapy Developer
Bristol-Myers Squibb
Biopharmaceutical and Nutritional Product R&D and Sales
European Commission
The European Commission, abbreviated as the EU Commission, is a supranational body under the European Union. Within the EU political system, the European Commission primarily undertakes executive tasks, thus being roughly equivalent to the government in a national system. However, the European Commission has other functions as well. In particular, except for the few circumstances specified in the treaties, the European Commission is the only institution with legislative power in the EU legislative process.
Source: Jike Yaowen
Today, Amgen announced that it has reached an agreement with Celgene and Bristol-Myers Squibb (BMS) to acquire Otezla (apremilast) for $13.4 billion. Otezla is the only oral, non-biologic therapy for the treatment of psoriasis and psoriatic arthritis.
Amgen believes that the benefits of acquiring Otezla include:
Strong strategic alignment with Amgen’s long-standing expertise in psoriasis and inflammation
This differentiated oral therapy serves as a strong complement to Amgen’s existing portfolio of innovative biologic agents and biosimilars for inflammation.
Otezla to Achieve at Least Double-Digit Average Sales Growth Over the Next Five Years
Accelerate Amgen’s Near-Term and Long-Term Revenue Growth
Highly aligned with Amgen’s global strategic objectives
Advancing Amgen’s Innovative “First-in-Class” Pipeline
Otezla is currently approved in the United States for three indications: the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet’s disease. Otezla has been approved in more than 50 countries outside the United States, including the European Union and Japan.
References
[1] MAmgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits. received Aug, 26th from http://investors.amgen.com/news-releases/news-release-details/amgen-acquire-otezlar-134-billion-cash-or-approximately-112
Original Title:Flash | Major: Amgen Acquires Celgene’s New Psoriatic Arthritis Drug Otezla for $13.4 Billion
*Disclaimer: This article was written by an author contributing to Sina Medical News. The views expressed are solely those of the author and do not represent the position of Sina Medical News.▽Follow [WuXi AppTecGermany】WeChat Official Account
